Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03478787 · ClinicalTrials.gov registry record · Phase 3
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study of Psoriasis, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 327
- Enrollment target
- 20
- Study locations
NCT03478787: Completed Phase 3 study of Psoriasis, sponsored by AbbVie.
NCT03478787 is a Phase 3 study of Psoriasis that has completed, run by AbbVie. The registered enrollment target is 327 participants, below the 486-participant average among 125 other Psoriasis trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03478787, a Phase 3 study of Psoriasis, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 327 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Primary Outcome
The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. T
Conditions Studied
Interventions
- DRUG risankizumab
- DRUG secukinumab
Study Locations (20)
California
- Bakersfield Derma & Skin Cance /ID# 202115 - Bakersfield
- Center for Dermatology Clin Res /ID# 202116 - Fremont
- Dermatology Res. Assoc., CA /ID# 202170 - Los Angeles
- UC Davis Health /ID# 202263 - Sacramento
- Medderm Associates /ID# 202162 - San Diego
Florida
- Tory P Sullivan, MD PA /ID# 202177 - North Miami Beach
- Renstar Medical Research /ID# 202113 - Ocala
- Progressive Medical Research /ID# 202183 - Port Orange
- Integrated Clinical Research LLC /ID# 202152 - West Palm Beach
Arizona
- Advanced Research Associates - Glendale /ID# 204335 - Glendale
- Alliance Dermatology and MOHs /ID# 204336 - Phoenix
Massachusetts
- ORA, Inc. /ID# 204342 - Andover
- Beth Israel Deaconess Medical Center /ID# 204340 - Boston
Connecticut
- UConn Health Main /ID# 201745 - Farmington
Kentucky
- Dermatology Specialists Resear /ID# 202145 - Louisville
Maryland
- Dermatology and Skin Cancer Specialists, LLC /ID# 203938 - Rockville
Minnesota
- Minnesota Clinical Study Center /ID# 202369 - New Brighton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2018-05-08 |
| Est. Completion | 2020-07-08 |
| Phase | Phase 3 |
What the finished NCT03478787 record still lists
NCT03478787 is an interventional study that assigns participants to a tested intervention. The registered 327 participants enrollment target is mid-sized for trials with a published cap, below the 486-participant average among 125 other Psoriasis trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which risankizumab is the first listed.
NCT03478787 names 20 study sites across 11 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03478787 about?
NCT03478787 is a clinical study titled "Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis". The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.
What is the current status of trial NCT03478787?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 327 participants. The study started on 2018-05-08. Estimated completion is 2020-07-08.
What conditions does trial NCT03478787 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03478787?
The interventions under investigation include: risankizumab (DRUG), secukinumab (DRUG).
Who is sponsoring clinical trial NCT03478787?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03478787 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03478787's enrollment target sits among peer trials
327 25th of 125 higher than 101 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486378 · 327 participants · Phase 2
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
- NCT06370182 · 327 participants · NA
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI